Mizetam (Atorvastatin, Ezetimibe)

Mizetam is used to manage lipid disorders by reducing low‑density lipoprotein cholesterol levels.

• Primary hypercholesterolemia: lowers LDL‑C and total cholesterol, helping achieve target lipid levels in patients with elevated cholesterol.
• Mixed dyslipidemia: reduces both LDL‑C and triglycerides while modestly raising HDL‑C, addressing combined lipid abnormalities.
• Familial hypercholesterolemia: provides significant LDL‑C reduction in genetically high‑cholesterol patients when diet and lifestyle alone are insufficient.

• Mizetam combines atorvastatin, which competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, with ezetimibe, which blocks the intestinal NPC1L1 transporter responsible for dietary cholesterol absorption, resulting in a synergistic reduction of circulating low‑density lipoprotein cholesterol.

Adverse reactions may occur with Mizetam and are categorized by frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal discomfort: including nausea, abdominal pain or diarrhea.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: transient increase in ALT/AST.
• Fatigue: general tiredness.
• Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with risk of renal failure.
• Acute liver injury: marked elevation of hepatic enzymes or jaundice.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Pancreatitis: abdominal pain with elevated pancreatic enzymes.
• Myopathy with marked CK elevation: muscle weakness with high creatine kinase.
• Hepatotoxicity: liver dysfunction requiring discontinuation.

Before prescribing Mizetam, clinicians should consider several safety measures.

• Liver function monitoring: assess baseline ALT/AST and repeat periodically.
• Muscle symptom assessment: evaluate any unexplained muscle pain, tenderness or weakness.
• Renal function evaluation: adjust use in patients with significant renal impairment.
• Contraindication review: avoid in active liver disease or unexplained persistent elevations of hepatic enzymes.
• Drug interaction check: review concomitant medications that may increase statin exposure.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mizetam may interact with other medicines; awareness of interaction severity guides management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may markedly increase atorvastatin levels.
• Gemfibrozil: significantly raises risk of myopathy and rhabdomyolysis.
• Cyclosporine: enhances statin exposure, increasing muscle toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.
• Digoxin: possible increase in serum digoxin concentrations.
• Other fibrates (e.g., fenofibrate): may modestly raise risk of muscle-related events.
• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption, affecting efficacy.